Leigh Syndrome Treatment Market: Increasing Cases of Genetic Disorders is projected to Boost the Business at a CAGR of 6.20% During Forecast Period

Pune, India, 2022/MRFR Press Release/- Market Research Future has a half-cooked research report on the global Leigh syndrome treatment market.

Leigh Syndrome Treatment Market Highlights

Leigh’s disease is a progressive neurometabolic disorder occurring often after a viral infection during childhood, however, it can also occur in teens and adults. It is usually diagnosed with the help of MRI of the brain, particularly of the midbrain and brainstem part. The child often appears normal at birth but symptoms begin to appear within a few months to a period of two years of age. These may be accompanied by other problems such as irritability, loss of appetite, vomiting, and seizures. Eventually, the child may also have heart, kidney, vision, and breathing complications. There are different forms of Leigh's disease, but all forms have a poor prognosis. Those with partial deficiencies have a better prognosis but may live to be 6 or 7 years of age. Most cases are fatal during childhood, although some individuals have survived to adolescence.

The Leigh Syndrome Treatment Market is anticipated to reach USD 192.62 Million by 2030 at a 6.20 % CAGR during the forecast period 2022-2030

The most common underlying cause is a defect in energy production in the brain. Inborn errors of metabolism have also been reported with Leigh syndrome. According to researchers the classical form of Leigh syndrome accounted for approximately 80 percent of cases. The prevalence of Leigh syndrome has been estimated at 1 in every 36,000-40,000 births.

Regional Analysis

Global Leigh syndrome treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.

The Americas dominated the global Leigh syndrome treatment market owing to the rising incidences of genetic disorders. The European market holds the second largest share of the global Leigh syndrome treatment market owing to the high prevalence rate of this disease in the Eastern European regions. The Asia Pacific is expected to be the fastest growing region and is anticipated to compete with the American market during the forecasted period 2017-2023. The Middle East & African market especially, the African region is expected to witness a poor growth owing to the lack of knowledge in the medical sector, and less development in medical facilities in the Middle East & Africa will have limited growth in the market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Leigh Syndrome Treatment Market Research Report

Segmentation

The Leigh syndrome treatment is segmented on the basis of diagnosis, treatment, and end-users.

On the basis of the diagnosis, the market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), laboratory test, and others. The laboratory test is divided into blood test, serum test, urine test, and others.

On the basis of the treatment, the market is segmented into medications, medical procedures, and surgery.

On the basis of the end-user, the market is segmented into hospital, research organizations, and academic institutes.

Key Players

Some of key the players in the global Leigh syndrome treatment market are GlaxoSmithKline Plc (GSK), Brother Enterprises (China), Huazhong Pharma (China), Zhejiang Tianxin (China),  Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), and others.